QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies
Soligenix (NASDAQ: SNGX), announces its inclusion in a BioMedWire editorial examining the urgent rise of chronic and rare diseases in aging populations. With more than 30 million Americans living with rare disorders that often lack FDA-approved treatments, demand for novel therapies continues to grow. Soligenix is advancing late-stage programs including HyBryte(TM) for cutaneous T-cell lymphoma, now in its final confirmatory trial, positioning the Company at the intersection of scientific innovation and evolving national health-policy priorities focused on chronic and rare conditions. To view the full press release, visit https://ibn.fm/wtnpc About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on…